cell transplantation (SCT), interval between either SCT or relapse and first DLI, patient's age at the time of DLI, and none turned out to be statistically significant. The effect of a functional spleen on DLI response was not addressed in their study.
Based on our previous experience in a splenectomized patient with CML, in whom a GVL reaction could not be obtained with escalating doses of DLI, we hypothesized the possible role of spleen in development of GVL and GVH reactions. Interestingly, splenectomy was not stressed at all in the literature among several factors that may influence DLI response.
Findings observed by other investigators supported an increased frequency of GVHD in splenectomized patients. [2] [3] [4] A significantly increased risk of post-transplant relapses in splenectomized patients with CML has been previously reported. 2 Unexpectedly, they observed a trend towards increased risk of GVHD, as well. Thus, increased relapse risk with an increased incidence of GVHD may point to a critical role of spleen in differentiating GVH and GVL reactions.
In our previous experience, a 16-year-old, splenectomized male with CML, who underwent allogeneic HSCT from matched sibling donor, failed to respond to escalating doses of DLIs in post-transplantation relapse at þ 14 months (4 Â 10 7 , 8 Â 10 7 , 1 Â 10 8 and 2 Â 10 8 CD3 þ T cells/kg, q4-8 weeks). The relapse was in chronic phase. Although grade I-II acute GVHD was observed following first DLI, no GVL reaction was noted. The remaining infusions were not associated with GVH or GVL reactions, in spite of concurrent a-interferon use. The patient underwent second transplantation and currently is in complete remission with 100% donor chimerism and negative bcr/abl transcripts at þ 28 months following the second transplant.
Upon our clinical observation of unresponsiveness to escalating doses of DLI in a splenectomized patient with CML in post-transplant relapse, we are raising the question of whether the spleen is an important organ in initiating and maintaining a GVL response, or perhaps in differentiating GVHD and GVL reactions on the basis of the previous literature 2 reporting an increased incidence of relapse and GVHD in previously splenectomized patients undergoing an allogeneic HSCT. On the other hand, the increased incidence of post-transplant relapses in splenectomized patients may reflect a more advanced pre-transplant stage of disease. Thus, a decreased response to DLI may be expected in splenectomized patients. In the absence of a splenic function, the patient might be unable to initiate a GVL response. CD4 þ T cells are involved in antileukemia response, and splenectomy may contribute to an increased relapse rates by removal of splenic CD4 þ T cells and decreased GVL reactivity, without an associated decrease in GVH reaction in which CD8 cells are suggested as effectors. 5 Studies have proposed that CD4 þ T cells can eliminate tumors through activation and recruitment of effector cells including macrophages, 6 and the removal of the spleen, a reservoir of macrophages, may further interfere with anti-tumor responses.
Based on these observations and postulations, further studies investigating the role of prior splenectomy in DLI response may be informative and the data of the study by Simula et al.
1 may further be analyzed related to splenectomy status of their patients and help to answer these questions.
D Uckan-Ç etinkaya 1 We read with interest the recent letter to the editor by Uckan-Ç etinkaya et al. 1 concerning an article we have recently published in this journal. 2 In this report, we investigated the factors affecting the dose required to achieve remission (effective cell dose (ECD)) in patients with chronic myeloid leukemia (CML) treated with donor lymphocyte infusions (DLI) in an escalating dose regimen (EDR), concluding that the response to DLI is dose dependent and that the main factors influencing the ECD are the disease stage at relapse and the degree of donor-recipient histocompatibility. be obtained, notwithstanding the development of acute graft-versus-host disease (GVHD), Uckan-Ç etinkaya et al. 1 hypothesized a possible role of the spleen in the balance between graft-versus-leukemia (GVL) and graft-versus-host (GVH) effect after DLI. Unfortunately, we do not have the opportunity to further analyze our data on the basis of this factor, as in our series none of the patients had previously undergone splenectomy.
We recently investigated the risk factors for GVHD after DLI administered with EDR in patients treated for CML in relapse following conventional allografting. 3 Two main factors emerged as predictors of the development of both grade II-IV acute and extensive chronic GVHD, the infusion of male recipients with lymphocytes from a female donor and the interval between transplant and the last DLI, but only the first remained significant at multivariate analysis. 4 However, even in this series, none of the patients previously had splenectomy. The lack of splenectomized subjects in the DLI series clearly reflects the current therapeutic approach to CML that makes splenectomy obsolete.
Interestingly, a previous retrospective study analyzed the role of pretransplant splenectomy among 358 consecutive patients receiving HLA genotypically identical marrow grafts for CML. 4 At multivariate analysis, the incidence of late infections and the incidence or severity of acute or chronic GVHD were not influenced by previous splenectomy. On the other hand, splenectomy was associated with an increased risk of leukemia relapse. However, most of splenectomized patients were also at an advanced stage of disease, thus making extremely difficult to dissect the contribution of each factor. I was excited to read the paper by Inami et al. 1 in a recent issue of Leukemia regarding the evolution of a rare case of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph þ CML) into polycythemia vera with 1849G4T mutation of the Janus kinase 2 (JAK2 V617F ) mutation. Contrary to the group's suggestion, this was not the first case of coexisting BCR-ABL translocation and JAK2 V617F mutation reported in the literature. In 2005, Curtin et al.
2 described a patient with essential thrombocythemia who developed Ph þ CML 12 years later. Despite achieving a major cytogenetic response, treatment with imatinib did not control the thrombocytosis. Subsequently, JAK2 V617F mutation was found in the bone marrow sample of this patient. 3 More recently (after the publication of Inami), Hussein et al. 4 presented a case of myelofibrosis with JAK2 V617F mutation emerging after successful treatment of Ph þ CML. Several previous reports of transformation of PhÀ myeloproliferative disorders into Ph þ CML and vice versa may also potentially harbor JAK2 V617F mutation if ever tested. 5, 6 While it is unclear at the moment if these occurrences are true associations or just coincidental, the recent finding that JAK2 may be an important therapeutic target for Ph þ CML adds further excitement to the encouraging rate of progress in this field.
